Accelerated Fractionation Plus Chemotherapy Versus Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer. 2021

Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; rades.dirk@gmx.net.

OBJECTIVE Prognosis of patients with unresectable squamous cell carcinomas of the head and neck requires improvement. This retrospective study compared accelerated radiotherapy plus chemotherapy to conventional radiochemotherapy. METHODS Patients received definitive treatment with accelerated radiotherapy plus chemotherapy (group A, n=10) or conventional cisplatin-based radiochemotherapy (group B, n=85). Groups were matched for several patient and tumor characteristics and compared for locoregional control (LRC), overall survival (OS) and toxicities. Additionally, accelerated radiotherapy plus chemotherapy and chemotherapy regimens in group B were compared for LRC and OS. RESULTS Treatment type had no significant impact on LRC (p=0.98) and OS (p=0.57). In group A, toxicities occurred more often, including grade ≥3 mucositis (p=0.041), grade ≥2 lymphedema (p=0.007) and grade ≥3 leucopenia (p=0.007). Best 2-year LRC (p=0.39) and OS (p=0.015) was achieved with 20 mg/m2 cisplatin days 1-5 every 4 weeks; accelerated radiochemotherapy resulted in second-worst outcomes. CONCLUSIONS Given the limitations of this study, accelerated radiotherapy plus chemotherapy provided no significant benefit but increased toxicity compared to conventional radiochemotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy

Related Publications

Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
October 2018, Radiation oncology (London, England),
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
June 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
March 2008, The New England journal of medicine,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
February 1993, The New England journal of medicine,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
February 1993, The New England journal of medicine,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
February 1993, The New England journal of medicine,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
July 1996, The British journal of cancer. Supplement,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
January 1990, Cancer treatment and research,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
January 1994, International journal of oncology,
Dirk Rades, and Carlos A Narvaez, and Stefan Janssen, and Ursula SchrÖder, and Karl L Bruchhage, and Samer G Hakim, and Tobias Bartscht, and Steven E Schild
January 2002, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!